Delivery Order SPE2DB24D2106-SPE2DB25FATYW

Award Date 11/1/24
Potential Completion Date 11/4/24
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,313.77 contract is for the supply of 4566838310 VYVANSE 50 MG CAPSULE 100S, with a performance period through January 6, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a range of...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $3,780.52 contract is for the delivery of 100 units of the prescription drug Vyvanse 10 mg capsules. The delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program, which enables the DLA to issue firm fixed-price delivery...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $1,724 contract is for the delivery of 100 capsules of the medication Vyvanse (70 mg) with an ultimate completion date of December 4, 2023. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm fixed-price...
The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract valued at $1,724.00 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Vyvanse 70 mg capsules to support the recurring medical supply needs of military health facilities. This delivery order falls under a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $1,110.17, is for the delivery of 100 units of the prescription drug Vyvanse 40 mg capsules. The award is associated with a larger indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $1,421.11 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 4566378209 VYVANSE 30 MG CAPSULE 100S, a prescription medication, to support the medical supply needs of military healthcare facilities. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $2,616.04, is for the delivery of 100 units of the 50 mg capsule form of the prescription drug Vyvanse. The contract is a firm fixed-price delivery order, with an ultimate completion date of May 9, 2024. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $3,448, is for the delivery of 100 units of 20 milligram Vyvanse capsules. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which runs through December 31, 2025. The IDC covers a wide...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of VYVANSE 40 MG CAPSULE 100S, a prescription medication, with a ceiling value of $2,119.08 and a period of performance through November 15, 2024. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which covers...
This contract award, valued at $1,164.82, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of 4565874491 - VYVANSE 10 MG CAPSULE 100S, with an ultimate completion date of September 20, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999,...
  • SPE2DB24D2106
    Indefinite Delivery Contract
  • SPE2DB24D2106-SPE2DB25FATYW
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,370.43 firm fixed-price contract is for the supply of Vyvanse 50 mg capsules.

DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This delivery order is not associated with any set-aside designation, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains. The contract has an ultimate completion date of November 4, 2024.

Generated 1/31/25, 9:12 AM